Absci Corporation reported its financial results for the second quarter of 2025, revealing a revenue of $0.6 million for the three months ending June 30, a decrease of 53% compared to $1.3 million in the same period of 2024. For the first half of 2025, revenue totaled $1.8 million, down 18% from $2.2 million in the prior year. The decline in revenue is attributed to the timing of project-based milestones and the mix of ongoing program activities under its drug creation agreements. The company incurred a net loss of $30.6 million for the second quarter, compared to a loss of $24.8 million in the same quarter of 2024, and a total net loss of $56.9 million for the first half of 2025, up from $46.7 million in the previous year.

Operating expenses for Absci increased to $32.0 million in the second quarter of 2025, a 14% rise from $28.0 million in the same quarter of 2024. Research and development expenses surged by 34% to $20.5 million, driven by advancements in drug creation programs and increased personnel costs. Selling, general, and administrative expenses decreased slightly by 9% to $8.5 million, primarily due to reduced stock-based compensation. The company’s accumulated deficit reached $566.5 million as of June 30, 2025, with cash and cash equivalents and short-term investments totaling $117.5 million.

Strategically, Absci has been focusing on its Integrated Drug Creation platform, which utilizes generative AI to enhance antibody therapeutics development. The company has initiated a Phase 1 clinical trial for its internally developed program ABS-101, aimed at treating Inflammatory Bowel Disease, and anticipates filing an Investigational New Drug application for ABS-201, targeting androgenetic alopecia, in the first half of 2026. Additionally, Absci entered a strategic collaboration with Advanced Micro Devices, Inc. (AMD) in January 2025, which included a $20 million investment from AMD to optimize the performance of its AI drug creation technologies.

As of June 30, 2025, Absci's workforce included 127,677,180 shares outstanding, reflecting an increase in employee headcount and stock-based compensation expenses. The company has also engaged in various financing activities, including an at-the-market offering program and a public offering, which collectively raised significant capital to support its operations. Looking ahead, Absci expects to continue incurring substantial expenses as it advances its drug development programs and seeks to expand its partnerships, while also navigating the uncertainties inherent in biopharmaceutical development.

About Absci Corp

About 10-Q Filings

A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.

Key points about the 10-Q:

  • Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
  • Content: It includes:
    • Financial statements showing the company's current financial position
    • Updates from management on the performance and projections of the business
    • Information about potential risks the company faces
    • Details on how the company is run internally
  • Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.